BioPharmSignal logoBioPharmSignal

Biotech News

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

Ocular Therapeutix (OCUL)Ocular TherapeutixEarnings

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, November 9, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.

Related news

OCULOcular Therapeutix2026-08-03 11:00 EST

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

LCTXLineage Cell Therapeutics2026-11-05 13:00 EST

Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

IRIXIRIDEX2026-11-03 21:05 EST

Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026

TARSTarsus Pharmaceuticals2026-10-29 20:30 EST

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OCGNOcugen2026-10-22 11:00 EST

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

LENZLenz Therapeutics Inc2026-10-22 12:00 EST

LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

SGHTSight Sciences2026-11-04 21:05 EST

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

TARSTarsus Pharmaceuticals2026-11-03 21:05 EST

Tarsus Reports Third Quarter 2026 Financial Results

View all latest news

Ocular Therapeutix

Sustained Ocular Drug Delivery Ocular Therapeutix develops bioresorbable hydrogel implants designed to deliver drugs within the eye for extended periods. Its lead franchise seeks to reduce the frequency of anti-VEGF injections for retinal vascular diseases. AXPAXLI AXPAXLI is an intravitreal hydrogel implant containing axitinib, a...

Recent company news

OCULOcular Therapeutix2026-11-06 12:00 EST

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OCULOcular Therapeutix2026-11-02 12:00 EST

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

OCULOcular Therapeutix2026-10-29 11:00 EST

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

OCULOcular Therapeutix2026-10-09 11:00 EST

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OCULOcular Therapeutix2026-10-01 11:00 EST

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

Stock data

Close
6.43 USD
Market cap
1.82B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States